Allos Receives US Patent For Folotyn

Allos has reported that the US Patent and Trademark Office (USPTO) has issued a patent for the use of Folotyn (pralatrexate injection) for the treatment of T-cell lymphoma.

US Patent No 7622470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025. Allos holds a worldwide license from these institutions to develop and market Folotyn for all indications.

The FDA has approved Folotyn for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Folotyn is the drug approved by the FDA for the indication based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated. The Folotyn approval was based on the results from Propel, an open-label, single-arm, multi-center, international clinical trial.

Marc Graboyes, senior vice president and general counsel of Allos Therapeutics, said: “We are pleased to add this important patent to our intellectual property portfolio for Folotyn. Patent protection is an essential component of our product life cycle management strategy, and this patent further strengthens the Folotyn franchise.”